Dr Annie Hasib PhD

Dr Annie Hasib

Institute of Metabolism and Systems Research
Postdoctoral Research Fellow

Contact details

Address
Institute of Metabolism and Systems Research
Institute of Biomedical Research
University of Birmingham
Edgbaston
Birmingham
B15 2TT
UK

Annie is a Postdoctoral Research Fellow in Professor David Hodson’s group. Her research aims to delineate the crosstalk between various islet endocrine cells and to identify novel mechanisms for preserving islet endocrine function in diabetes.

Qualifications

  • PhD in Life and health sciences, Ulster University, 2017
  • MSc in Biotechnology, Ulster University, 2013
  • B.Tech in Biotechnology, Amity University, 2012

Biography

Annie was awarded VCRS scholarship at Ulster University to pursue her PhD research, which focussed on evaluating the potential of multi-agonist gut derived peptides in obesity and diabetes. After completing her PhD in 2017, she worked as a postdoctoral research assistant at University of Dundee on a Diabetes UK funded project to identify the role of extracellular matrix remodelling in the pathogenesis of insulin resistance. She was recently awarded an early career Research Grant from Society for Endocrinology for studies on extracellular matrix regulation in the islets. Since January 2020, Annie is working as a postdoctoral research fellow in Islet Biology Lab led by Professor David Hodson at the University of Birmingham.

Research

Annie’s current research aims to understand the developmental crosstalk between islet endocrine cells to maintain normal glucose levels in the body. Using state of the art imaging techniques and transgenic murine models, her work focusses on unravelling novel mechanistic insights into preserving islet endocrine function and survival in diabetes.

Research Groups and Centres

Publications

Viloria K, Nasteska D, Briant LJ, Heising S, Larner DP, Fine NH, Ashford FB, da Silva Xavier G, Ramos MJ, Hasib A, Cuozzo F, Fox JEM, MacDonald PE, Akerman I, Lavery GG, Flaxman C, Morgan NG, Richardson SJ, Hewison M and Hondson DJ (2020) Vitamin-D-Binding Protein Contributes to the Maintenance of α Cell Function and Glucagon Secretion. Cell reports 31(11):107761.

Hasib A (2020) Multiagonist Unimolecular Peptides for Obesity and Type 2 Diabetes: Current Advances and Future Directions.
Clinical Medicine Insights: Endocrinology and Diabetes 13, p.1179551420905844.

Hasib A, Hennayake CK, Bracy DP, Bugler-Lamb AR, Lantier L, Khan F, Ashford MLJA, McCrimmon RJ, Wasserman DH and Kang L (2019) CD44 contributes to hyaluronan-mediated insulin resistance in skeletal muscle of high fat-fed C57BL/6 mice. American Journal of Physiology-Endocrinology and Metabolism 317(6):E973-83.

Khan D, Kelsey R, Maheshwari RR, Stone VM, Hasib A, Koivula FN, Watson A, Harkin S, Irwin N, Shaw JA, McClenaghan NH, Venglovecz V, Ébert A,  Flodström-Tullberg M, White MG and Kelly K (2019) Short-term CFTR inhibition reduces islet area in C57BL/6 mice. Scientific reports 9(1):1-1.

Hasib A, Khan D, Craig SL, Gault VA, Flatt PR and Irwin N (2019) Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice. European Journal of Pharmacology 865:172733.

Hasib A, Ng MT, Tanday N, Craig SL, Gault VA, Flatt PR and Irwin N (2019) Exendin‐4 (Lys27PAL)/gastrin/xenin‐8‐Gln: A novel acylated GLP‐1/gastrin/xenin hybrid peptide that improves metabolic status in obese‐diabetic (ob/ob) mice. Diabetes/metabolism research and reviews 35(3):e3106.

Hasib A, Ng MT, Khan D, Gault VA, Flatt PR and Irwin N (2018) Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln. European journal of pharmacology 834:126-35.

Hasib A, Ng MT, Khan D, Gault VA, Flatt PR and Irwin N (2018) A novel GLP-1/xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice. Peptides 100:202-11.

 Hasib A, Ng MT, Gault VA, Khan D, Parthsarathy V, Flatt PR and Irwin N (2017) An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice. Diabetologia, 60(3), pp.541-552.                                                                                                                          

Parthsarathy V, Irwin N, Hasib A, Martin CM, McClean S, Bhat VK, Ng MT, Flatt PR and Gault VA (2016) A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties. Biochimica et Biophysica Acta (BBA)-General Subjects 1860(4), pp.757-764.       

View all publications in research portal

Culture and collections

Schools, institutes and departments

Services and facilities